A new immunotherapy called a Reovirus is being used in combination with Standard Myeloma Drugs in an early clinical trial. This reovirus helps boost tumor-fighting activities and has been studied with both allogeneic and autologous transplant. Researchers are now combining this reovirus, called Reolysin, with other standard myeloma drugs without transplant. Last December, results from [...]
This post first appeared on Page Not Found - The Myeloma Crowd, please read the originial post: here
